65.74 0.00 (0.00%)
After hours: 5:25PM EST
|Bid||65.58 x 800|
|Ask||65.90 x 1300|
|Day's Range||65.33 - 65.96|
|52 Week Range||60.32 - 82.72|
|Beta (3Y Monthly)||1.24|
|PE Ratio (TTM)||15.76|
|Earnings Date||Apr 29, 2019 - May 3, 2019|
|Forward Dividend & Yield||2.52 (3.82%)|
|1y Target Est||80.67|
GILD or ABBV: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Revenue and EPS growth trajectoryGilead Sciences (GILD) reported revenue of $22.13 billion in 2018, a YoY (year-over-year) fall of 15.24%. The company also reported
GILD or ABBV: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Comparing dividend projectionsGilead Sciences (GILD) and AbbVie (ABBV) reported dividends per share of $2.28 and $3.59, respectively, in 2018.According to Gilead
Biotech leaders are facing growth challenges in 2019 as pricing pressure continues and their biggest drugs face looming patent expirations. Analysts say they will need to innovate — or buy.
GILD or ABBV: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Expense guidance for 2018 In its fourth-quarter earnings presentation, Gilead Sciences (GILD) guided for SG&A (selling, general and administrative) expenses of
Xeljanz recently ran into a safety problem, but investors aren't sure if this will open doors for similar drugs in development, or slam them shut.
GILD or ABBV: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)EPS guidance for 2019In its fourth-quarter earnings presentation, Gilead Sciences (GILD) guided for a GAAP (generally accepted accounting principles) to non-GAAP
GILD or ABBV: Which Is a Better Biotech Pick This Month?Share price movementsOn February 15, Gilead Sciences (GILD) closed at $67.59, 1.84% higher than its previous closing price, 12.05% higher than its 52-week low of $60.32, and 18.29% lower than
Key highlights of the past week are regulatory and pipeline developments along with research collaboration deals.
Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
Intercept Pharmaceuticals stock popped Tuesday after its liver disease treatment succeeded in a Phase 3 study — a week after Gilead Sciences failed in the same area, known as NASH.
The New York-based drugmaker announced Tuesday that its medicine Ocaliva is the first to succeed in a final stage trial for nonalcoholic steatohepatitis (NASH), a liver disease that many drugmakers are targeting for potentially lucrative treatments. The drug may be the only available treatment for NASH for more than a year if it wins FDA approval. Intercept’s drug has side effects, and NASH is shaping up to be an especially tricky market.
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) — which is a frontrunner along with Gilead Sciences, Inc. (NASDAQ: GILD) in the non-alcoholic steatohepatitis drug development race — reported positive top-line results Tuesday for a late-stage study of its pipeline asset Ocaliva, chemically obeticholic acid. Intercept said Ocaliva 25 mg, which is being evaluated in a late-stage study dubbed REGENERATE, achieved the primary endpoint of demonstrating statistically significant improvement in liver fibrosis without worsening of NASH at 18 months. Primary efficacy analysis also revealed a numerically greater proportion of patients in the treatment arm met the primary endpoint of NASH resolution with no worsening of liver fibrosis relative to the control arm, although it did not achieve statistical significance.
Gilead Receives Approval in Canada for YESCARTA™ (Axicabtagene Ciloleucel) CAR T Therapy for Adults With Relapsed or Refractory Large B-cell Lymphoma After Two or More Lines of Systemic Therapy
The U.S. Centers for Medicare & Medicaid Services (CMS) on Friday proposed coverage of expensive CAR-T cell therapies at cancer centers that meet criteria including a registry or clinical study to monitor how well patients fare for at least two years after treatment. New hospital payment terms from Medicare, the federal government healthcare program for the elderly and disabled, are expected later in the year. If the proposal is finalized, use of CAR-Ts for Medicare patients could continue to be limited to the largest regional cancer centers.
Announcement: Moody's announces completion of a periodic review of ratings of Gilead Sciences, Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Gilead Sciences, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Under a new proposal by the Centers for Medicare & Medicaid Services, the Medicare program would cover FDA-approved CAR-T therapies. CAR-T, or chimeric anitgen receptor T-cell, therapies use genetically-engineered immune cells called T cells to more specifically target cancer cells. CMS said the proposal, announced Friday, would require Medicare to cover the cancer treatment when it is offered in a CMS-approved registry or clinical study, as long as data is collected from the patients for at least two years after treatment. CMS said it plans to use the information to decide what treatments are most beneficial to patients and which CAR-T therapies to fund in the future. "Today's proposed coverage decision would improve access to this therapy while deepening CMS's understanding of how patients in Medicare respond to it, so the agency can ensure that it is paying for CAR T-cell therapy for cases in which the benefits outweigh the risks," said CMS Administrator Seema Varma in a statement. There are currently only two approved CAR-T therapies in the U.S., and both are very expensive. Novartis's Kymriah has a list price of $475,000, while and Gilead Sciences Inc.'s Yescarta is priced at $373,000. There is no national Medicare policy for covering the expensive new cancer treatment, so it is currently up to local Medicare administrative contractors to decide whether to pay for it. Shares of Novartis have gained 4.3% in the year to date, while shares of Gilead have gained 6.3%. The SPDR S&P Pharmaceuticals ETF has gained 13.5% and the S&P 500 has gained 10.4%.
An RBC Capital Markets analyst is "head over heels" for five biotech stocks, two with high Relative Strength Ratings. In afternoon action in the stock market, biotech stocks inched up.
Shares of Viking Therapeutics (NASDAQ:VKTX) are making headlines this week after an announcement from Gilead Sciences (NASDAQ:GILD), that one of its drugs did not meet the primary endpoints of its Phase 3 clinical trial. This gave a possible opening to Viking Therapeutics, which gave a boost to VKTX stock.Source: Shutterstock Does that make it a buy? Let's examine the stock a bit more closely. If you haven't heard of VKTX stock before, don't feel guilty. With a market cap of just $650 million, it's not a well-known company. It's not a Bristol-Myers Squibb (NYSE:BMY), Celgene (NASDAQ:CELG), Biogen (NASDAQ:BIIB) or another large cap biotech company. Breaking Down VKTX StockViking Therapeutics is a self-described "clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders." The company is working on several treatments, one of which includes enrolling VK2809, which is aimed at fatty liver and hypercholesterolemia, in a Phase 2 study. Gilead's Selonsertib liver treatment failed its Phase 3 clinical trial earlier this week, thus giving some hope to VKTX stock.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 U.S. Stocks That Are Coming to Life Again The company also has VK5211, "an orally available, non-steroidal SARM designed to selectively stimulate muscle and bone formation."At the end of the day, Viking Therapeutics has some intriguing developments in its pipeline. But at the same time, this is also a speculative biotech company. Investors are, to some degree, betting on a binary event. Either VKTX stock is a multi-bagger with big-time potential if it gains regulatory approval and/or is acquired by a larger company, or neither of those things happen and it's a total dud. That's the nature of the beast with young biotech stocks.Case in point? Viking Therapeutics stock doesn't have any revenue. Its pipeline is promising, but that's all investors are betting on at this point. There's no real way to evaluate the business because there is no business! At least in the traditional sense. VKTX has enough money in the bank to fund its operations for the time being, but its future hinges solely on its treatments. Trading VKTX StockHopefully the chart above doesn't seem too complex. I only wanted to lay out a few different levels and prior trends that played a role in VKTX stock over the last 12 months.Like most of the market, VKTX came into Q4 near its highs, although admittedly under some pressure already. Still, the stock was pummeled along with the S&P 500 and other major market indices as Q4 got under way. VKTX stock price bottomed near $7 on Christmas Eve and has been working higher since.VKTX stock is now over the 50-day and 21-day moving averages. For traders and investors that are going in on this, perhaps consider using a $7 as a key reference level. Below this mark and Viking Therapeutics stock could be in trouble.As much as I want to say that the stock is okay over uptrend support (purple line) and moving average support -- and really, it is -- know that this is a speculative position that is subject to extreme moves in both directions. These moves can appear overnight and there's little investors can do about it other than planning ahead with proper position sizing. * Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks? For those that don't want such a speculative position, consider choosing between two companies like Celgene and Gilead.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 U.S. Stocks That Are Coming to Life Again * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 5 Tips to Become a Better Stock Trader Compare Brokers The post Should You Buy Viking Therapeutics After Gilead Drug Failure? appeared first on InvestorPlace.
With Gilead Sciences, Inc. (NASDAQ: GILD )'s NASH setback, Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT )'s Ocaliva, which is being evaluated in a late-stage study for NASH with fibrosis, is taking the ...
Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.
When Gilead Sciences (NASDAQ:GILD) reported earnings earlier this month, shares stagnated a bit but stayed above the 50-day moving average. That gave investors a reasonable level to measure against. However, Gilead stock is lower on Tuesday following disappointing drug data.Specifically, Gilead's selonsertib drug failed its phase 3 clinical trial. Even though GILD stock is off the lows, that's causing selling pressure on Tuesday and brings up a more broad question: Which stock is better, Gilead or Celgene (NASDAQ:CELG)? * The 7 Best Video Game Stocks to Power Up Your Portfolio! I believe the latter offers a better value right now, despite the fact that Bristol-Myers Squibb (NYSE:BMY) has already announced that it will buy Celgene. Let's look at both stocks more closely.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sizing Up Gilead StockWhen Gilead reported fourth-quarter earnings, it missed analysts' earnings expectations of $1.69 per share by 25 cents and reported a 2.5% decline in sales. For 2019, analysts are currently forecasting a 30 basis point decline in sales, following a more than 15% decline in 2018. Further, they expect roughly flat earnings growth from last year's non-GAAP earnings of $6.67 per share.That's not all that great, but considering the stock trades at roughly 10 times this year earnings, at least aren't paying an egregious valuation. Further, at least the year-over-year declines are abating, unlike 2018's haircut.In other words, while Gilead doesn't have an attractive growth profile, it's likely put the worst behind it and is looking at moving forward. Plus, the stock yields about 3.75%, not bad in most investors' eyes. The company has $31.5 billion in cash and roughly the same amount in long-term debt. Finally, while Gilead stock still kicks off a solid amount of free-cash flow, it's been under notable pressure over the past few years. Why Celgene Stock Looks Better To be fair, it's not a simple argument that Gilead stock is trash and Celgene is great. In fact, Celgene has its own issues too, but it helps that BMY is there with a bid. It also helps that Celgene has growth.Analysts expect Celgene to grow sales 11.7% this year and 12.8% in 2020. On the earnings front, consensus expectations call for 18.7% growth in both years. That's pretty impressive when you think it, particularly when you consider that CELG stock trades at 8.5 times this year's earnings estimate.While Celgene may not pay a dividend like Gilead stock, shares are cheaper and have far better growth. Free cash flow is trending higher (not lower) as well. Now for the buyout.Bristol-Myers will pay $50 per share in cash, plus give one share of BMY for each share of CELG. At current prices, that values CELG at about $100 per share. Celgene also receives a $2 billion breakup fee if the deal falls through and shareholders could receive an additional $9 per share should three of Celgene's treatments achieve various milestones. * 9 U.S. Stocks That Are Coming to Life Again Assuming the deal goes through, let's also not forget that converting to BMY stock wouldn't be the worst thing the world. Either way, with CELG still trading at a discount to the takeover price, investors are getting a good deal. The big downside is if the deal doesn't go through. That's a risk that doesn't come with Gilead stock and should that happen, CELG shares will likely plunge in response.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 7 Forever Stocks to Buy for Long-Term Gains * 5 Self-Driving Car Stocks to Buy Compare Brokers The post Celgene vs. Gilead Stock: What's the Better Biotech Buy? appeared first on InvestorPlace.